Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USANA Acquires BabyCare For Faster Route To China

This article was originally published in PharmAsia News

Executive Summary

Multi-level dietary supplement marketer USANA Health Sciences chooses a faster route over the "arduous" licensing approach to enter China by acquiring nutritional product firm BabyCare Ltd

You may also be interested in...



Herbalife Rides Daily Consumption To Q2 Earnings Jump, Revised Guidance

Herbalife's daily consumption model is bearing substantial fruit across many of its 73 markets, driving record sales and prompting a significant earnings guidance hike

Sales & Earnings In Brief

OTCs fill pharma gap for Bayer: Lower sales of Rx pharmaceuticals in the U.S., attributable to generic competition for some drugs, are counterbalanced by the "particularly pleasing growth" of Bayer HealthCare's Consumer Health segment, says Chairman Werner Wenning. During a July 29 call, Wenning noted OTC business grew 6 percent in the firm's fiscal 2010 second quarter, with Bayer Aspirinup 6 percent and Aleve up 14.3 percent. Sales of the One A Day multivitamin line, which expanded in May with the launch of Men's Pro Edge formula, grew 14.8 percent. Wenning attributed the consumer product growth to economic recovery and increased consumption in the U.S. Bayer HealthCare reported overall quarterly sales rose 6.4 percent, adjusted for currency exchange, to 4.31 billion euros ($5.6 billion under July 29 conversion rates). The German chemical and pharmaceutical giant's first-half health care sales gained 3.6 percent to reach $10.6 billion

China Takes "Baby Steps" Toward More Open Supplement Regulation

China's health product regulators are taking "baby steps" toward more streamlined approval of supplements, but multi-ingredient products likely will face a series of hurdles before market, says Jeff Crowther, former executive director of the Natural Products Association's Beijing office

Related Content

UsernamePublicRestriction

Register

SC075773

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel